Degron Therapeutics vs Supernus Pharmaceuticals
Degron Therapeutics vs Supernus Pharmaceuticals, compared side by side on 16 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Degron Therapeutics is on 62/100 and Supernus Pharmaceuticals on 60/100.
Where each one leads
Degron Therapeutics
- funding raised: $40.0M against $17.5M
Supernus Pharmaceuticals
- agent readiness: 41/100 against 27/100
- domain rating: 67/100 against 25/100
- headcount: 809 against 24
At a glance
| Measure | Degron Therapeutics | Supernus Pharmaceuticals |
|---|---|---|
| What it is | Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines. | Biopharmaceutical company developing and commercializing CNS disease treatments. |
| Category | Biotechnology, Pharmaceuticals, Drug Discovery, Healthcare | Biotechnology, Pharmaceuticals, Healthcare, Neuroscience |
| Sells toBusiness model | B2B | B2B |
| Offering | Platform | Services |
| Founded | 2020 | 2005 |
| Headquarters | San Diego, USA | Rockville, United States |
| Status | Active | Active |
Size, funding and growth
| Measure | Degron Therapeutics | Supernus Pharmaceuticals |
|---|---|---|
| Employees | 24 | 809 |
| Total funding | $40.0M | $17.5M |
| Latest round | Series A Extension | Series A |
| Valuation | $1.1B | Not published |
| LinkedIn followers | 1,380 | Not published |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | Degron Therapeutics | Supernus Pharmaceuticals |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 62/100 | 60/100 |
| Traction | Not published | 56/100 |
| Team | 24/100 | 30/100 |
| Search visibility | 57/100 | 15/100 |
| Quality | Not published | 78/100 |
| Agent readinessHow well an AI agent can read and act on the site | F (27/100) | D (41/100) |
| Domain ratingLink authority, 0-100 | 25/100 | 67/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | Degron Therapeutics | Supernus Pharmaceuticals |
|---|---|---|
| Hosting | Self Managed | AWS |
| Frameworks | Not detected | Tailwind CSS, Bootstrap |
| Analytics | Not detected | Google Tag Manager |
Degron Therapeutics vs Supernus Pharmaceuticals: common questions
Which is better, Degron Therapeutics or Supernus Pharmaceuticals?
On our 0-100 score Degron Therapeutics rates higher (62/100 against 60/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 16 data points above: read the rows that match what you are buying for.
How do Degron Therapeutics and Supernus Pharmaceuticals compare on the numbers?
Degron Therapeutics leads on funding raised ($40.0M against $17.5M). Supernus Pharmaceuticals leads on agent readiness (41/100 against 27/100), domain rating (67/100 against 25/100), headcount (809 against 24).
Read the full Degron Therapeutics review and pricing or the Supernus Pharmaceuticals review and pricing. You can also browse other Degron Therapeutics alternatives we track.